For the quarter ending 2025-09-30, SLN made $5,446,000 in revenue. -$20,958,000 in net income. Net profit margin of -384.83%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | - | - | 142,000 | 10,814,500 |
| Segment reporting, other segment item, amount | - | - | 121,000 | 4,713,750 |
| Other r&d costs | - | 936,000 | 584,000 | 1,119,500 |
| Personnel research and development costs | - | 4,479,000 | 5,556,000 | 5,125,750 |
| Contracted development costs | - | 12,232,000 | 14,673,000 | 10,725,500 |
| Revenue | 159,000 | - | - | - |
| Cost of sales | 64,000 | - | 54,000 | 2,952,500 |
| Gross profit | 95,000 | - | - | - |
| Research and development costs | 20,544,000 | - | - | - |
| General and administrative expenses | 5,795,000 | - | 7,684,000 | 6,721,000 |
| Restructuring charges | 0 | - | - | - |
| Operating loss | -26,244,000 | - | - | - |
| Foreign currency gain/(loss), net | 1,934,000 | - | - | - |
| Other income, net | 770,000 | - | - | - |
| Benefit from r&d credit | 2,583,000 | - | - | - |
| Loss before income tax expense | -20,957,000 | - | - | - |
| Income tax expense | 1,000 | - | - | 211,250 |
| Net loss | -20,958,000 | -27,354,000 | -28,530,000 | -11,327,250 |
| Earnings per share, basic | -0.15 | -0.19 | -0.2 | -0.083 |
| Earnings per share, diluted | -0.15 | -0.19 | -0.2 | -0.083 |
| Weighted average number of shares outstanding, basic | 141,701,848 | 141,696,047 | 141,678,734 | 34,688,056 |
| Weighted average number of shares outstanding, diluted | 141,701,848 | 141,696,047 | 141,678,734 | 34,688,056 |
Silence Therapeutics plc (SLN)
Silence Therapeutics plc (SLN)